ZVRA — Zevra Therapeutics Balance Sheet
0.000.00%
- $253.21m
- $243.49m
- $27.46m
Annual balance sheet for Zevra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3.22 | 4.21 | 112 | 82.8 | 67.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.86 | 2.58 | 1.53 | 8.3 | 17.4 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6.63 | 8.38 | 115 | 92.8 | 86.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.01 | 2.39 | 2.02 | 1.78 | 1.53 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 10.5 | 11.2 | 133 | 115 | 172 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.43 | 7.54 | 4.23 | 12 | 73.7 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 85 | 77.6 | 5.82 | 40.2 | 110 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | -74.5 | -66.4 | 127 | 75.1 | 61.9 |
Total Liabilities & Shareholders' Equity | 10.5 | 11.2 | 133 | 115 | 172 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |